(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Green Inflections: A Manual for Inside Plants - 2Vote In favor of Your Favored Sort Of Bevarage
- 3Vote In favor of Your Favored Distributed computing Administration
- 4Genesis Marks 10th Anniversary With Magma GT Concept Aimed at High-Performance Flagships
- 5They died 'doing what they loved': The stories of workers in their 80s who died on the job
- From Amateur to Master: My Involvement in Photography
- A Manual for Well known Western television Series
- Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
- Dick Van Dyke shares his secrets to longevity as he turns 100
- Manual for Tracking down Spending plan Agreeable Travel Objections
- Nature's Treats: 10 Organic products That Lift Prosperity
- Manual for Tracking down the Nearby Business sectors and Marketplaces
- Why doing good also makes us feel good, during the holidays and beyond
- Step by step instructions to Prepare with Senior Protection for Inward feeling of harmony.
